Monday, September 16, 2024
9/16/2024
Non-alcoholic fatty liver disease (NAFLD) is a growing metabolic disorder that is closely associated with obesity and insulin resistance/type 2 diabetes. NAFLD begins with a simple hepatic steatosis, which in some individuals may progress to nonalcoholic steatohepatitis (NASH), an advanced abnormity that may further lead to fibrosis, cirrhosis, liver failure or cancer. Whereas enhanced de novo lipogenesis and fatty acid influx initiate the hepatic steatosis, hepatic inflammation triggers the transition from hepatic steatosis to NASH and is an important driving force of the pathological progression towards fibrogenesis. However, the exact mechanisms underlying the development and progression of NAFLD remain poorly understood. While numerous studies have been devoted to the evaluation of genetic factors involved in obesity and its associated complications such as NAFLD, much is unknown about epigenetic changes in this process. Epigenetic regulation, including histone acetylation, is a molecular link between environmental factors (e.g., diets) and complex diseases (e.g., NAFLD). Histone deacetylase 1 (HDAC1) acts to remove acetyl groups from lysine residues in histones, thereby inhibiting gene expression. Our preliminary data suggested that liver-specific deletion of HDAC1 decreased hepatic lipid accumulation, inflammation and fibrosis in mice. Therefore, we hypothesize that HDAC1 plays a central role in the development of NAFLD. Aim 1 will determine the role of HDAC1 in promoting hepatic steatosis. We have generated genetic models with liver specific deletion or overexpression of HDAC1. We will determine: 1) whether and how liver-specific deletion of HDAC1 prevents, whereas specific overexpression of HDAC1 promotes hepatic steatosis in mice; 2) whether down-regulation of the transcriptional repressor KLF3 mediates the effect of HDAC1 in promoting hepatic lipid storage via regulation of PPARγ. Aim 2 will determine the role of HDAC1 in promoting hepatic inflammation in the development of NASH. Hepatic inflammation triggers the transition from hepatic steatosis to NASH. We will determine: 1) whether liver-specific deletion of HDAC1 prevents, whereas specific overexpression of HDAC1 promotes NASH in mice; 2) whether down-regulation of the transcriptional repressor KLF3 mediates the effect of HDAC1 in promoting hepatic chemotaxis and inflammation via regulation of C-Jun. Aim 3 will determine the mechanism underlying regulation of HDAC1 by excess nutrients. O-GlcNAcylation has emerged as a key nutrient sensor that regulates cellular metabolic pathways in response to over-nutritional cues. We will determine whether HDAC1 O-GlcNAcylation by excess nutrients such as glucose and saturated fatty acids, levels of which are commonly elevated in obesity, increases HDAC1 protein stability by preventing ubiquitination and proteasomal degradation, leading to enhanced HDAC1 protein content and activity. This project will define the role of HDAC1 as a nutrient sensor that regulates hepatic lipid metabolism and inflammation in the development and progression of NFALD. Our studies could guide the development of the epigenetic regulation as new therapeutic targets in the treatment of NAFLD.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
